<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9602489</journal-id>
<journal-id journal-id-type="pubmed-jr-id">20500</journal-id>
<journal-id journal-id-type="nlm-ta">Invert Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Invert. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Invertebrate neuroscience : IN</journal-title>
</journal-title-group>
<issn pub-type="ppub">1354-2516</issn>
<issn pub-type="epub">1439-1104</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29845318</article-id>
<article-id pub-id-type="pmc">6233307</article-id>
<article-id pub-id-type="doi">10.1007/s10158-018-0211-9</article-id>
<article-id pub-id-type="manuscript">NIHMS995205</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>egl-4</italic> modulates electroconvulsive seizure duration in <italic>C. elegans</italic></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Risley</surname>
<given-names>Monica G.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kelly</surname>
<given-names>Stephanie P.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Minnerly</surname>
<given-names>Justin</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jia</surname>
<given-names>Kailiang</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Dawson-Scully</surname>
<given-names>Ken</given-names>
</name>
<!--<email>ken.dawson-scully@fau.edu</email>-->
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL 33431, USA</aff>
<aff id="A2"><label>2</label>International Max-Planck Research School (IMPRS) for Brain and Behavior, Boca Raton, FL 33431, USA</aff>
<author-notes>
<fn fn-type="COI-statement" id="FN1">
<p id="P21"><bold>Conflict of interest</bold> The authors declare that they have no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>31</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<day>30</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>13</day>
<month>11</month>
<year>2018</year>
</pub-date>
<volume>18</volume>
<issue>2</issue>
<fpage>8</fpage>
<lpage>8</lpage>
<!--elocation-id from pubmed: 10.1007/s10158-018-0211-9-->
<abstract id="ABS1">
<p id="P1">Increased neuronal excitability causes seizures with debilitating symptoms. Effective and noninvasive treatments are limited for easing symptoms, partially due to the complexity of the disorder and lack of knowledge of specific molecular faults. An unexplored, novel target for seizure therapeutics is the cGMP/protein kinase G (PKG) pathway, which targets downstream K<sup>+</sup> channels, a mechanism similar to Retigabine, a recently FDA-approved antiepileptic drug. Our results demonstrate that increased PKG activity decreased seizure duration in <italic>C. elegans</italic> utilizing a recently developed electroconvulsive seizure assay. While the fly is a well-established seizure model, <italic>C. elegans</italic> are an ideal yet unexploited model which easily uptakes drugs and can be utilized for high-throughput screens. In this study, we show that treating the worms with either a potassium channel opener, Retigabine or published pharmaceuticals that increase PKG activity, significantly reduces seizure recovery times. Our results suggest that PKG signaling modulates downstream K<sup>+</sup> channel conductance to control seizure recovery time in <italic>C. elegans.</italic> Hence, we provide powerful evidence, suggesting that pharmacological manipulation of the PKG signaling cascade may control seizure duration across phyla.</p>
</abstract>
<kwd-group>
<kwd>
<italic>C. elegans</italic>
</kwd>
<kwd>Seizure</kwd>
<kwd>Epilepsy</kwd>
<kwd>Protein kinase G</kwd>
<kwd>PKG</kwd>
<kwd>Electroconvulsive seizure</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>